Glyco-engineered Expression Systems

Glyco-engineered Expression Systems

With years of research in Glycoengineering, CD BioGlyco has accumulated extensive experience. We have successfully developed efficient and stable plant, mammalian, and fungal expression systems to meet our clients' glycoprotein production needs.


Glycosylation is the process of attaching carbohydrates to proteins or lipids under the control of enzymes. Two main types of glycosylation are common: 1) N-glycosylation (attached to the nitrogen of the asparagine or arginine side chain); 2) O-glycosylation (attached to the hydroxyl oxygen of serine, threonine, tyrosine, hydroxylysine, or hydroxyproline side chain). Most secreted proteins in eukaryotes are modified by glycosylation. The number and structure of glycans affect protein folding, intracellular trafficking, and solubility. Therefore, glycosylation has a huge impact on the biological activity of glycoprotein and we should control carefully it during the manufacturing process to achieve optimal therapeutic effects.

During glycosylation, glycans mature in a species-dependent or tissue-dependent manner. The glycosylation patterns of glycoproteins vary greatly depending on the host species, cell type, and physiological state. Therefore, the host-specific differences of glycans are particularly important. Different mature glycan structures are obtained when the same polypeptide is expressed in different hosts. Current expression platforms for glycoprotein drugs generally do not produce homogeneous glycans, which easily leads to adverse side effects. Therefore, in recent years, scientists have made a lot of efforts to apply glycoengineering techniques to different expression systems to produce homogeneous therapeutic glycoproteins.

Fig.1 Overview of glycoengineering strategies.Fig.1 Overview of glycoengineering strategies. (Narimatsu, et al., 2021)

Glyco-engineered Expression Systems

Glycoengineering of expression systems is increasingly recognized as an important strategy for improving glycoprotein drugs. For better production of homogeneous recombinant glycoproteins, CD BioGlyco has applied glycoengineering to mammalian cells, Pichia pastoris, plant, and insect cell expression systems. Our mammalian expression systems include human cell lines, Chinese hamster ovary cells (CHO), and small hamster kidney cells (BHK). We apply glycoengineering techniques to the N. benthamiana expression system to generate target glycoproteins. In addition, we also provide clients with high-quality glycoengineered-Pichia pastoris expression system.

Advantages of Us

  • Plant, mammalian, and fungal-based expression vectors
  • Efficient and stable production services
  • Customized solutions to meet your specific needs
  • Experienced scientists

CD BioGlyco is a leading service provider specializing in efficient and stable glycoengineered expression systems. We have plant, mammalian, and fungal expression vectors for glycoprotein production. If you are interested in our glycoengineered expression systems, please contact us for more information.


  1. Narimatsu, Y.; et al. Genetic glycoengineering in mammalian cells. Journal of Biological Chemistry. 2021, 296.
  2. Dicker, M.; Strasser, R. Using glyco-engineering to produce therapeutic proteins. Expert Opinion on Biological Therapy. 2015, 15(10):1501-1516.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.